Omics meets hypothesis-driven research

 

 Buy Article Permissions and Reprints

Summary

The emergence of omics technologies allowing the global analysis of a given biological or molecular system, rather than the study of its individual components,has revolutionized biomedical research, including cardiovascular medicine research in the past decade. These developments raised the prospect that classical,hypothesis-driven,single gene-based approaches may soon become obsolete. The experience accumulated so far, however, indicates that omic technologies only represent tools similar to those classically used by scientists in the past and nowadays, to make hypothesis and build models, with the main difference that they generate large amounts of unbiased information.Thus,omics and classical hypothesis-driven research are rather complementary approaches with the potential to effectively synergize to boost research in many fields, including cardiovascular medicine. In this article we discuss some general aspects of omics approaches, and review contributions in three areas of vascular biology, thrombosis and haemostasis, atherosclerosis and angiogenesis, in which omics approaches have already been applied (vasculomics).

• References

• 1 Weinstein JN. 'Omic' and hypothesis-driven research in the molecular pharmacology of cancer. Curr Opin Pharmacol 2002; 02: 361-365.
  CrossrefPubMedGoogle Scholar
• 2 Evans GA. Designer science and the ”omic“ revolution. Nat Biotechnol 2000; 18: 127.
  CrossrefPubMedGoogle Scholar
• 3 Ideker T, Galitski T, Hood L. A new approach to decoding life: systems biology. Annu Rev Genomics Hum Genet 2001; 02: 343-372.
  CrossrefPubMedGoogle Scholar
• 4 Yu U, Lee SH, Kim YJ. et al. Bioinformatics in the post-genome era. J Biochem Mol Biol 2004; 37: 75-82.
  PubMedGoogle Scholar
• 5 Sotiriou C, Piccart MJ. Taking gene-expression profiling to the clinic: when will molecular signatures become relevant to patient care?. Nat Rev Cancer 2007; 07: 545-553.
  CrossrefPubMedGoogle Scholar
• 6 Farmer P, Bonnefoi H, Becette V. et al. Identification of molecular apocrine breast tumours by microarray analysis. Oncogene 2005; 24: 4660-4671.
  CrossrefPubMedGoogle Scholar
• 7 Subramanian A, Tamayo P, Mootha VK. et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci USA 2005; 102: 15545-15550.
  CrossrefPubMedGoogle Scholar
• 8 Mootha VK, Lindgren CM, Eriksson KF. et al. PGC-1alpha-responsive genes involved in oxidative phosphorylation are coordinately downregulated in human diabetes. Nat Genet 2003; 34: 267-273.
  CrossrefPubMedGoogle Scholar
• 9 Nelson PS, Clegg N, Arnold H. et al. The program of androgen-responsive genes in neoplastic prostate epithelium. Proc Natl Acad Sci USA 2002; 99: 11890-11895.
  CrossrefPubMedGoogle Scholar
• 10 Doane AS, Danso M, Lal P. et al. An estrogen receptor-negative breast cancer subset characterized by a hormonally regulated transcriptional program and response to androgen. Oncogene 2006; 25: 3994-4008.
  CrossrefPubMedGoogle Scholar
• 11 Gospodarowicz M, Benedet L, Hutter RV. et al. History and international developments in cancer staging. Cancer Prev Control 1998; 02: 262-268.
  PubMedGoogle Scholar
• 12 Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000; 100: 57-70.
  CrossrefPubMedGoogle Scholar
• 13 Vogelstein B, Kinzler KW. The multistep nature of cancer. Trends Genet 1993; 09: 138-141.
  CrossrefPubMedGoogle Scholar
• 14 Liu ET. Classification of cancers by expression profiling. Curr Opin Genet Dev 2003; 13: 97-103.
  CrossrefPubMedGoogle Scholar
• 15 Nuyten DS, van de Vijver MJ. Using microarray analysis as a prognostic and predictive tool in oncology: focus on breast cancer and normal tissue toxicity. Semin Radiat Oncol 2008; 18: 105-114.
  CrossrefPubMedGoogle Scholar
• 16 Alaiya AA, Franzen B, Auer G. et al. Cancer proteomics: from identification of novel markers to creation of artifical learning models for tumor classification. Electrophoresis 2000; 21: 1210-1217.
  CrossrefPubMedGoogle Scholar
• 17 Ludwig JA, Weinstein JN. Biomarkers in cancer staging, prognosis and treatment selection. Nat Rev Cancer 2005; 05: 845-856.
  CrossrefPubMedGoogle Scholar
• 18 Troy GC. An overview of hemostasis. Vet Clin North Am Small Anim Pract 1988; 18: 5-20.
  CrossrefPubMedGoogle Scholar
• 19 Ferrer-Antunes C. Polymorphisms of coagulation factor genes--a review. Clin Chem Lab Med 1998; 36: 897-906.
  PubMedGoogle Scholar
• 20 Anderson L, Anderson NG. High resolution two-dimensional electrophoresis of human plasma proteins. Proc Natl Acad Sci USA 1977; 74: 5421-5425.
  CrossrefPubMedGoogle Scholar
• 21 Omenn GS. The Human Proteome Organization Plasma Proteome Project pilot phase: reference specimens, technology platform comparisons, and standardized data submissions and analyses. Proteomics 2004; 04: 1235-1240.
  CrossrefPubMedGoogle Scholar
• 22 Berhane BT, Zong C, Liem DA. et al. Cardiovascular-related proteins identified in human plasma by the HUPO Plasma Proteome Project pilot phase. Proteomics 2005; 05: 3520-3530.
  CrossrefPubMedGoogle Scholar
• 23 Scully MF. Plasma peptidome: A new approach for assessing thrombotic risk?. Thromb Haemost 2006; 96: 697.
  Article in Thieme ConnectPubMedGoogle Scholar
• 24 Dittrich M, Birschmann I, Stuhlfelder C. et al. Understanding platelets. Lessons from proteomics, genomics and promises from network analysis. Thromb Haemost 2005; 94: 916-925.
  Article in Thieme ConnectPubMedGoogle Scholar
• 25 Dittrich M, Birschmann I, Pfrang J. et al. Analysis of SAGE data in human platelets: features of the transcriptome in an anucleate cell. Thromb Haemost 2006; 95: 643-651.
  Article in Thieme ConnectPubMedGoogle Scholar
• 26 Barelli S, Crettaz D, Thadikkaran L. et al. Plasma/ serum proteomics: pre-analytical issues. Expert Rev Proteomics 2007; 04: 363-370.
  CrossrefPubMedGoogle Scholar
• 27 Ayache S, Panelli M, Marincola FM. et al. Effects of storage time and exogenous protease inhibitors on plasma protein levels. Am J Clin Pathol 2006; 126: 174-184.
  CrossrefPubMedGoogle Scholar
• 28 Tammen H, Mohring T, Kellmann M. et al. Mass spectrometric phenotyping of Val 34Leu polymorphism of blood coagulation factor XIII by differential peptide display. Clin Chem 2004; 50: 545-551.
  CrossrefPubMedGoogle Scholar
• 29 Mann KG, Brummel-Ziedins K, Undas A. et al. Does the genotype predict the phenotype? Evaluations of the hemostatic proteome. J Thromb Haemost 2004; 02: 1727-1734.
  CrossrefPubMedGoogle Scholar
• 30 Pula G, Perera S, Prokopi M. et al. Proteomic analysis of secretory proteoins and vesicles in vascular research. Proteomics Clin Appl 2008 2008; 02: 882-889.
  PubMedGoogle Scholar
• 31 Piccin A, Murphy WG, Smith OP. Circulating microparticles: pathophysiology and clinical implications. Blood Rev 2007; 21: 157-171.
  CrossrefPubMedGoogle Scholar
• 32 Smalley DM, Root KE, Cho H. et al. Proteomic discovery of 21 proteins expressed in human plasma-derived but not platelet-derived microparticles. Thromb Haemost 2007; 97: 67-80.
  Article in Thieme ConnectPubMedGoogle Scholar
• 33 Tuomisto TT, Binder BR, Yla-Herttuala S. Genetics, genomics and proteomics in atherosclerosis research. Ann Med 2005; 37: 323-332.
  CrossrefPubMedGoogle Scholar
• 34 Monajemi H, Arkenbout EK, Pannekoek H. Gene expression in atherogenesis. Thromb Haemost 2001; 86: 404-412.
  Article in Thieme ConnectPubMedGoogle Scholar
• 35 Martinez-Gonzalez J, Rius J, Castello A. et al. Neuron-derived orphan receptor-1 (NOR-1)modulates vascular smooth muscle cell proliferation. Circ Res 2003; 92: 96-103.
  CrossrefPubMedGoogle Scholar
• 36 Arkenbout EK, van Bragt M, Eldering E. et al. TR3 orphan receptor is expressed in vascular endothelial cells and mediates cell cycle arrest. Arterioscler Thromb Vasc Biol 2003; 23: 1535-1540.
  CrossrefPubMedGoogle Scholar
• 37 van Thienen JV, Fledderus JO, Dekker RJ. et al. Shear stress sustains atheroprotective endothelial KLF2 expression more potently than statins through mRNA stabilization. Cardiovasc Res 2006; 72: 231-240.
  CrossrefPubMedGoogle Scholar
• 38 Yan FF, Liu YF, Liu Y. et al. KLF4: a novel target for the treatment of atherosclerosis. Med Hypotheses 2008; 70: 845-847.
  CrossrefPubMedGoogle Scholar
• 39 Lutgens E, Faber B, Schapira K. et al. Gene profiling in atherosclerosis reveals a key role for small inducible cytokines: validation using a novel monocyte chemoattractant protein monoclonal antibody. Circulation 2005; 111: 3443-3452.
  CrossrefPubMedGoogle Scholar
• 40 Mayr M, Zampetaki A, Sidibe A. et al. Proteomic and metabolomic analysis of smooth muscle cells derived from the arterial media and adventitial progenitors of apolipoprotein E-deficient mice. Circ Res 2008; 102: 1046-1056.
  CrossrefPubMedGoogle Scholar
• 41 Wu J, Liu W, Sousa E. et al. Proteomic identification of endothelial proteins isolated in situ from atherosclerotic aorta via systemic perfusion. J Proteome Res 2007; 06: 4728-4736.
  CrossrefPubMedGoogle Scholar
• 42 Skogsberg J, Lundstrom J, Kovacs A. et al. Transcriptional profiling uncovers a network of cholesterol-responsive atherosclerosis target genes. PLoS Genet 2008; 04: e1000036.
  CrossrefPubMedGoogle Scholar
• 43 Blanco-Colio LM, Martin-Ventura JL, Vivanco F. et al. Biology of atherosclerotic plaques: what we are learning from proteomic analysis. Cardiovasc Res 2006; 72: 18-29.
  CrossrefPubMedGoogle Scholar
• 44 Sung HJ, Ryang YS, Jang SW. et al. Proteomic analysis of differential protein expression in atherosclerosis. Biomarkers 2006; 11: 279-290.
  CrossrefPubMedGoogle Scholar
• 45 Almofti MR, Huang Z, Yang P. et al. Proteomic analysis of rat aorta during atherosclerosis induced by high cholesterol diet and injection of vitamin D3. Clin Exp Pharmacol Physiol 2006; 33: 305-309.
  CrossrefPubMedGoogle Scholar
• 46 Bagnato C, Thumar J, Mayya V. et al. Proteomics analysis of human coronary atherosclerotic plaque: a feasibility study of direct tissue proteomics by liquid chromatography and tandem mass spectrometry. Mol Cell Proteomics 2007; 06: 1088-1102.
  CrossrefPubMedGoogle Scholar
• 47 Wilson AM, Kimura E, Harada RK. et al. Beta2-microglobulin as a biomarker in peripheral arterial disease: proteomic profiling and clinical studies. Circulation 2007; 116: 1396-1403.
  CrossrefPubMedGoogle Scholar
• 48 Duran MC, Martin-Ventura JL, Mas S. et al. Characterization of the human atheroma plaque secretome by proteomic analysis. Methods Mol Biol 2007; 357: 141-150.
  PubMedGoogle Scholar
• 49 Karlsson H, Leanderson P, Tagesson C. et al. Lipo-proteomics II: mapping of proteins in high-density lipoprotein using two-dimensional gel electrophoresis and mass spectrometry. Proteomics 2005; 05: 1431-1445.
  CrossrefPubMedGoogle Scholar
• 50 Karlsson H, Leanderson P, Tagesson C. et al. Lipoproteomics I: mapping of proteins in low-density lipoprotein using two-dimensional gel electrophoresis and mass spectrometry. Proteomics 2005; 05: 551-565.
  CrossrefPubMedGoogle Scholar
• 51 Yang PY, Rui YC, Yang PY. et al. Proteomic analysis of foam cells. Methods Mol Biol 2007; 357: 297-305.
  PubMedGoogle Scholar
• 52 Fach EM, Garulacan LA, Gao J. et al. In vitro biomarker discovery for atherosclerosis by proteomics. Mol Cell Proteomics 2004; 03: 1200-1210.
  CrossrefPubMedGoogle Scholar
• 53 Mayr M, Madhu B, Xu Q. Proteomics and metabolomics combined in cardiovascular research. Trends Cardiovasc Med 2007; 17: 43-48.
  CrossrefPubMedGoogle Scholar
• 54 Miller DT, Ridker PM, Libby P. et al. Atherosclerosis: the path from genomics to therapeutics. J Am Coll Cardiol 2007; 49: 1589-1599.
  CrossrefPubMedGoogle Scholar
• 55 Carmeliet P. Angiogenesis in health and disease. Nat Med 2003; 09: 653-660.
  CrossrefPubMedGoogle Scholar
• 56 Mittal V, Nolan DJ. Genomics and proteomics approaches in understanding tumor angiogenesis. Expert Rev Mol Diagn 2007; 07: 133-147.
  CrossrefPubMedGoogle Scholar
• 57 Korherr C, Gille H, Schafer R. et al. Identification of proangiogenic genes and pathways by high-throughput functional genomics: TBK1 and the IRF3 pathway. Proc Natl Acad Sci USA 2006; 103: 4240-4245.
  CrossrefPubMedGoogle Scholar
• 58 Jih YJ, Lien WH, Tsai WC. et al. Distinct regulation of genes by bFGF and VEGF-A in endothelial cells. Angiogenesis 2001; 04: 313-321.
  CrossrefPubMedGoogle Scholar
• 59 Abe M, Sato Y. cDNA microarray analysis of the gene expression profile of VEGF-activated human umbilical vein endothelial cells. Angiogenesis 2001; 04: 289-298.
  CrossrefPubMedGoogle Scholar
• 60 Schoenfeld J, Lessan K, Johnson NA. et al. Bioinformatic analysis of primary endothelial cell gene array data illustrated by the analysis of transcriptome changes in endothelial cells exposed to VEGF-A and PlGF. Angiogenesis 2004; 07: 143-156.
  CrossrefPubMedGoogle Scholar
• 61 St Croix B, Rago C, Velculescu V. et al. Genes expressed in human tumor endothelium. Science 2000; 289: 1197-1202.
  CrossrefPubMedGoogle Scholar
• 62 Seaman S, Stevens J, Yang MY. et al. Genes that distinguish physiological and pathological angiogenesis. Cancer Cell 2007; 11: 539-554.
  CrossrefPubMedGoogle Scholar
• 63 Ghilardi C, Chiorino G, Dossi R. et al. Identification of novel vascular markers through gene expression profiling of tumor-derived endothelium. BMC Genomics 2008; 09: 201.
  CrossrefPubMedGoogle Scholar
• 64 Bhati R, Patterson C, Livasy CA. et al. Molecular characterization of human breast tumor vascular cells. Am J Pathol 2008; 172: 1381-1390.
  CrossrefPubMedGoogle Scholar
• 65 Abdollahi A, Hahnfeldt P, Maercker C. et al. Endostatin's antiangiogenic signaling network. Mol Cell 2004; 13: 649-663.
  CrossrefPubMedGoogle Scholar
• 66 Favre CJ, Mancuso M, Maas K. et al. Expression of genes involved in vascular development and angiogenesis in endothelial cells of adult lung. Am J Physiol Heart Circ Physiol 2003; 285: H1917-1938.
  CrossrefPubMedGoogle Scholar
• 67 Hardwick JS, Yang Y, Zhang C. et al. Identification of biomarkers for tumor endothelial cell proliferation through gene expression profiling. Mol Cancer Ther 2005; 04: 413-425.
  CrossrefPubMedGoogle Scholar
• 68 Sessa C, Guibal A, Del Conte G. et al. Biomarkers of angiogenesis for the development of antiangiogenic therapies in oncology : tools or decorations?. Nat Clin Pract Oncol. 2008 05. in press.
  PubMedGoogle Scholar
• 69 Bruneel A, Labas V, Mailloux A. et al. Proteomic study of human umbilical vein endothelial cells in culture. Proteomics 2003; 03: 714-723.
  CrossrefPubMedGoogle Scholar
• 70 Li A, Li H, Jin G. et al. A proteomic study on cell cycle progression of endothelium exposed to tumor conditioned medium and the possible role of cyclin D1/E. Clin Hemorheol Microcirc 2003; 29: 383-390.
  PubMedGoogle Scholar
• 71 Bruneel A, Labas V, Mailloux A. et al. Proteomics of human umbilical vein endothelial cells applied to etoposide-induced apoptosis. Proteomics 2005; 05: 3876-3884.
  CrossrefPubMedGoogle Scholar
• 72 Godl K, Gruss OJ, Eickhoff J. et al. Proteomic characterization of the angiogenesis inhibitor SU6668 reveals multiple impacts on cellular kinase signaling. Cancer Res 2005; 65: 6919-6926.
  CrossrefPubMedGoogle Scholar
• 73 Thompson LJ, Wang F, Proia AD. et al. Proteome analysis of the rat cornea during angiogenesis. Proteomics 2003; 03: 2258-2266.
  CrossrefPubMedGoogle Scholar
• 74 Roesli C, Mumprecht V, Neri D. et al. Identification of the surface-accessible, lineage-specific vascular proteome by two-dimensional peptide mapping. Faseb J. 2008 in press.
  PubMedGoogle Scholar
• 75 Castronovo V, Waltregny D, Kischel P. et al. A chemical proteomics approach for the identification of accessible antigens expressed in human kidney cancer. Mol Cell Proteomics 2006; 05: 2083-2091.
  CrossrefPubMedGoogle Scholar
• 76 Park HJ, Kim BG, Lee SJ. et al. Proteomic profiling of endothelial cells in human lung cancer. J Proteome Res 2008; 07: 1138-1150.
  CrossrefPubMedGoogle Scholar
• 77 Dean RA, Butler GS, Hamma-Kourbali Y. et al. Identification of candidate angiogenic inhibitors processed by matrix metalloproteinase 2 (MMP-2) in cell-based proteomic screens: disruption of vascular endothelial growth factor (VEGF)/heparin affin regulatory peptide (pleiotrophin) and VEGF/Connective tissue growth factor angiogenic inhibitory complexes by MMP-2 proteolysis. Mol Cell Biol 2007; 27: 8454-8465.
  CrossrefPubMedGoogle Scholar
• 78 Simonson AB, Schnitzer JE. Vascular proteomic mapping in vivo. J Thromb Haemost 2007; 05 (Suppl. 01) 183-187.
  CrossrefPubMedGoogle Scholar
• 79 Acevedo L, Yu J, Erdjument-Bromage H. et al. A new role for Nogo as a regulator of vascular remodeling. Nat Med 2004; 10: 382-388.
  CrossrefPubMedGoogle Scholar
• 80 Delbosc S, Haloui M, Louedec L. et al. Proteomic analysis permits the identification of new biomarkers of arterial wall remodeling in hypertension. Mol Med 2008; 14: 383-394.
  PubMedGoogle Scholar
• 81 Ribatti D, Vacca A, Roncali L. et al. The chick embryo chorioallantoic membrane as a model for in vivo research on angiogenesis. Int J Dev Biol 1996; 40: 1189-1197.
  PubMedGoogle Scholar
• 82 Hagedorn M, Javerzat S, Gilges D. et al. Accessing key steps of human tumor progression in vivo by using an avian embryo model. Proc Natl Acad Sci USA 2005; 102: 1643-1648.
  CrossrefPubMedGoogle Scholar
• 83 Jin SW, Herzog W, Santoro MM. et al. A transgene-assisted genetic screen identifies essential regulators of vascular development in vertebrate embryos. Dev Biol 2007; 307: 29-42.
  CrossrefPubMedGoogle Scholar
• 84 Lee P, Goishi K, Davidson AJ. et al. Neuropilin-1 is required for vascular development and is a mediator of VEGF-dependent angiogenesis in zebrafish. Proc Natl Acad Sci USA 2002; 99: 10470-10475.
  CrossrefPubMedGoogle Scholar
• 85 Kidd KR, Weinstein BM. Fishing for novel angiogenic therapies. Br J Pharmacol 2003; 140: 585-594.
  CrossrefPubMedGoogle Scholar
• 86 Rubinstein AL. Zebrafish: from disease modeling to drug discovery. Curr Opin Drug Discov Devel 2003; 06: 218-223.
  PubMedGoogle Scholar
• 87 Ny A, Autiero M, Carmeliet P. Zebrafish and Xenopus tadpoles: small animal models to study angiogenesis and lymphangiogenesis. Exp Cell Res 2006; 312: 684-693.
  CrossrefPubMedGoogle Scholar
• 88 De Smet F, Carmeliet P, Autiero M. Fishing and frogging for anti-angiogenic drugs. Nat Chem Biol 2006; 02: 228-229.
  CrossrefPubMedGoogle Scholar
• 89 Lawson ND, Weinstein BM. In vivo imaging of embryonic vascular development using transgenic zebrafish. Dev Biol 2002; 248: 307-318.
  CrossrefPubMedGoogle Scholar
• 90 Link V, Shevchenko A, Heisenberg CP. Proteomics of early zebrafish embryos. BMC Dev Biol 2006; 06: 1.
  CrossrefPubMedGoogle Scholar
• 91 Lemeer S, Pinkse MW, Mohammed S. et al. Online automated in vivo zebrafish phosphoproteomics: from large-scale analysis down to a single embryo. J Proteome Res 2008; 07: 1555-1564.
  CrossrefPubMedGoogle Scholar
• 92 Bosworth CAt, Chou CW, Cole RB. et al. Protein expression patterns in zebrafish skeletal muscle: initial characterization and the effects of hypoxic exposure. Proteomics 2005; 05: 1362-1371.
  CrossrefPubMedGoogle Scholar
• 93 Nicoli S, Ribatti D, Cotelli F. et al. Mammalian tumor xenografts induce neovascularization in zebrafish embryos. Cancer Res 2007; 67: 2927-2931.
  CrossrefPubMedGoogle Scholar
• 94 Stoletov K, Klemke R. Catch of the day: zebrafish as a human cancer model. Oncogene 2008; 27: 4509-4520.
  CrossrefPubMedGoogle Scholar
• 95 Nagamine K, Matsuda A, Asashima M. et al. XRASGRP2 expression during early development of Xenopus embryos. Biochem Biophys Res Commun 2008; 372: 886-891.
  CrossrefPubMedGoogle Scholar
• 96 Sato K, Iwasaki T, Sakakibara K. et al. Towards the molecular dissection of fertilization signaling: Our functional genomic/proteomic strategies. Proteomics 2002; 02: 1079-1089.
  CrossrefPubMedGoogle Scholar